Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature

Authors

  • Anne-Charlotte Niesert Department of Dermatology and Allergy, University Hospital, LMU Munich, DE-80337 Munich, Germany
  • Anne Guertler
  • Olga Schutti
  • Laura Engels
  • Michael Flaig
  • Lars E. French
  • Max Schlaak
  • Markus Reinholz

DOI:

https://doi.org/10.2340/00015555-3840

Keywords:

lichen planus, melanoma, pembrolizumab, immune-related adverse event, anti-PD-1, anti-PD-L1

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019. Eur J Cancer 2020; 126: 159-177.

DOI: https://doi.org/10.1016/j.ejca.2019.11.015

FDA approval timeline of active immunotherapies. Cancer Research Institute; 2020. [Date accessed September 30, 2020] Available from: https://www.cancerresearch.org/scientists/immuno-oncology-landscape/fda-approval-timeline-of-active-immunotherapies.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378: 1789-1801.

DOI: https://doi.org/10.1056/NEJMoa1802357

Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis 2020; 7: 359-369.

DOI: https://doi.org/10.1016/j.gendis.2020.02.002

Squibb BM. CheckMate -577, a phase 3 trial evaluating opdivo (nivolumab) as adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer, meets primary endpoint of disease-free survival 2020. [Date accessed September 30, 2020] Available from: https://news.bms.com/news/details/2020/CheckMate--577-a-Phase-3-Trial-Evaluating-Opdivo-nivolumab-as-Adjuvant-Therapy-for-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Meets-Primary-Endpoint-of-Disease-Free-Survival/default.aspx.

Squibb BM. Opdivo (nivolumab) significantly improves disease free-survival vs. placebo as adjuvant therapy for patients with high-risk, muscle-invasive urothelial carcinoma in phase 3 CheckMate -274 Trial 2020. [Date accessed September 30, 2020] Available from: https://news.bms.com/news/corporate-financial/2020/Opdivo-nivolumab-Significantly-Improves-Disease-Free-Survival-vs.-Placebo-as-Adjuvant-Therapy-for-Patients-with-High-Risk-Muscle-Invasive-Urothelial-Carcinoma-in-Phase-3-CheckMate--274-Trial/default.aspx.

Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254-263.

DOI: https://doi.org/10.1097/CCO.0000000000000290

Schwager Z, Stern M, Cohen J, Femia A. Clinical epidemiology and treatment of lichen planus: a retrospective review of 2 tertiary care centers. J Am Acad Dermatol 2019; 81: 1397-1399.

DOI: https://doi.org/10.1016/j.jaad.2019.04.027

Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345-361.

DOI: https://doi.org/10.1007/s40257-017-0336-3

Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020; 83: 1255-1268.

DOI: https://doi.org/10.1016/j.jaad.2020.03.132

Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 2018; 10: 1758835918764628.

DOI: https://doi.org/10.1177/1758835918764628

Levine O, Devji T, Xie F. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. Hum Vaccin Immunother 2017; 13: 1765-1767.

DOI: https://doi.org/10.1080/21645515.2017.1322241

de Lorenzi C, Andre R, Vuilleumier A, Kaya G, Abosaleh M. Bullous lichen planus and anti-programmed cell death-1 therapy: case report and literature review. Ann Dermatol Venereol 2020; 147: 221-227.

DOI: https://doi.org/10.1016/j.annder.2019.07.008

Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin Oncol 2019; 46: 362-371.

DOI: https://doi.org/10.1053/j.seminoncol.2019.10.003

Additional Files

Published

2021-06-02

How to Cite

Niesert, A.-C., Guertler, A., Schutti, O., Engels, L., Flaig, M., French, L. E., … Reinholz, M. (2021). Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature. Acta Dermato-Venereologica, 101(6), adv00472. https://doi.org/10.2340/00015555-3840

Issue

Section

Short Communication

Categories